for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis AG

NOVN.S

Latest Trade

85.51CHF

Change

-0.63(-0.73%)

Volume

5,376,369

Today's Range

85.11

 - 

86.19

52 Week Range

76.96

 - 

96.20

As of on the Virt-X ∙ Minimum 15 minute delay

Pricing

Previous Close
86.14
Open
86.00
Volume
5,376,369
3M AVG Volume
120.32
Today's High
86.19
Today's Low
85.11
52 Week High
96.20
52 Week Low
76.96
Shares Out (MIL)
2,291.77
Market Cap (MIL)
215,284.50
Forward P/E
16.86
Dividend (Yield %)
3.27

Next Event

Q3 2019 Novartis AG Earnings Release

Latest Developments

More

EMA Says CHMP Recommends Conditional Marketing Authorisation For Ebola Vaccine Ervebo

Vectura Says UK Court Dismissed GSK's Claims Of Passing Off In Respect Of Sandoz's Airflusal Forspiro

Novartis Reports Additional Positive Data From Cosentyx Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Industry

Major Drugs

Contact Info

Lichtstrasse 35

+41.61.3241111

https://www.novartis.com/

Executive Leadership

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Alex Krauer

Honorary Chairman of the Board

Daniel L. Vasella

Honorary Chairman of the Board

Vasant Narasimhan

Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

Independent Non-Executive Vice Chairman of the Board

Key Stats

2.18 mean rating - 28 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

48.5K

2017

49.1K

2018

51.9K

2019(E)

47.2K
EPS (USD)

2016

4.710

2017

4.860

2018

5.150

2019(E)

5.153
Price To Earnings (TTM)
29.78
Price To Sales (TTM)
4.36
Price To Book (MRQ)
3.86
Price To Cash Flow (TTM)
16.77
Total Debt To Equity (MRQ)
58.86
LT Debt To Equity (MRQ)
43.01
Return on Investment (TTM)
6.79
Return on Equity (TTM)
5.26

Latest News

Latest News

Novartis gets FDA boost in crowded eye drug market

Novartis's anti-blindness medicine Beovu has become the latest eye drug to win U.S. Food and Drug Administration approval, giving the Swiss drugmaker a boost in the increasingly competitive market for eye problems among an aging population.

Novartis gets U.S. approval for eye drug Beovu

Novartis has received approval from the U.S. Food and Drug Administration for its Beovu drug to treat a cause of vision loss, the Swiss pharmaceuticals company said on Tuesday.

Novartis says Kisqali boosts survival in breast cancer patients

Novartis said on Sunday that Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes will help convince doctors to choose its drug over Pfizer's blockbuster Ibrance.

Novartis blames former AveXis executives for Zolgensma data manipulation

Novartis AG <NOVN.S> blamed former executives Brian and Allan Kaspar for the manipulation of data behind its $2.1 million gene therapy Zolgensma, saying they either personally manipulated the data or pressured subordinates into doing so.

Novartis blames former Avexis execs for Zolgensma manipulation

Novartis AG laid the blame for the manipulation of data behind its $2.1 million gene therapy Zolgensma at the feet of the former executives Brian and Allan Kaspar, who it alleges either personally manipulated the data or pressured subordinates to manipulate the data.

Novartis halts distribution of its Zantac versions amid probe into impurities

Novartis AG's <NOVN.S> Sandoz unit said on Wednesday it was halting distribution of its versions of the drug commonly known as Zantac in all its markets, including the United States and Canada, after contaminants were found in the heartburn drug.

Novartis MS drug cuts relapse rate by half compared to Sanofi medicine

Novartis's investigational multiple sclerosis drug ofatumumab cut the relapse rate in patients by more than half in trials comparing it to Sanofi's Aubagio as the Swiss drugmaker aims to refresh its portfolio of medicines in neurological diseases.

Novartis CEO promises to speed data integrity disclosures

Novartis <NOVN.S> Chief Executive Vas Narasimhan, facing an uproar over data manipulation involving $2.1 million gene therapy Zolgensma, pledged on Monday to tell regulators quickly if credible questions emerge in future over data integrity.

Novartis CEO pledges to speed data integrity disclosures

Novartis Chief Executive Vas Narasimhan promised to inform U.S. regulators quickly if credible questions emerge internally over data integrity, he told investors on Monday, following data manipulation allegations involving the Swiss drugmaker's $2.1 million gene therapy...

Novartis wins FDA's breakthrough tag for lung cancer hopeful

Novartis has secured the U.S. Food and Drug Administration's Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.

UPDATE 1-Novartis joins Pfizer with FDA fast-track tag for lung cancer hopeful

Novartis has nabbed the U.S. Food and Drug Administration's breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a tough-to-treat mutated lung cancer type.

Novartis sees cell, gene therapy reaching up to 15% of sales in midterm

Novartis sees cell and gene therapies accounting for up to 15% of its total revenue in the midterm from a much lower level at present, a Swiss newspaper reported on Wednesday, after the Swiss drugmaker held an event with German-language media on research and development.

Swiss stocks - Factors to watch on September 4

Here are some of the main factors that may affect Swiss stocks on Wednesday:

UK cost watchdog recommends Novartis' blindness therapy Luxturna

Novartis AG's gene therapy for blindness, Luxturna, is recommended for use on England's public health service, the country's healthcare cost-effectiveness watchdog NICE said on Tuesday.

Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals

Swiss drugmakers Novartis and Lonza separately deepened their push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments.

Novartis's Sandoz licenses proposed multiple sclerosis biosimilar

Swiss drugmaker Novartis's Sandoz division has licensed from Polpharma Biologics a proposed biosimilar version of multiple sclerosis drug natalizumab, the companies said on Tuesday without giving financial details of the accord.

Novartis takes aim at Roche's star MS drug

Swiss drugmaker Novartis on Friday stepped up its challenge to Roche's multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its cross-town rival's drug Ocrevus.

Novartis begins hunt for piece of Roche's growing MS empire

Novartis on Friday announced positive study results for its prospective multiple sclerosis drug ofatumumab that the Swiss drugmaker hopes will pose a stiff challenge to Roche's medicine Ocrevus in a highly competitive market.

UPDATE 1-Eye care company Alcon posts $390 mln Q2 loss as taxes bite

Alcon posted a second-quarter loss as the Swiss-listed eye care company paid more in taxes, amortised intangible assets and took charges linked to its spin-off from former parent Novartis.

Novartis to answer U.S. Senate demand for data manipulation details

Novartis plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up